ALK and lung adenocarcinoma: The availability of standardized protocols for ALK rearrangement detection using the BP6165 concentrated antibody on the LYNX480 PLUS platform will expand the number of laboratories that can determine the eligibility of patients with lung adenocarcinoma for treatment with ALK tyrosine kinase inhibitors in a reliable and concordant manner.